[PDF][PDF] Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double …
TJ Lynch, I Bondarenko, A Luft… - Journal of clinical …, 2012 - ose-immuno.com
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, M Sebastian, J Neal…
Journal of clinical oncology, 2012•ose-immuno.comPurpose Ipilimumab, which is an anti–cytotoxic T-cell lymphocyte-4 monoclonal antibody,
showed a survival benefit in melanoma with adverse events (AEs) managed by protocol-
defined guidelines. A phase II study in lung cancer assessed the activity of ipilimumab plus
paclitaxel and carboplatin.
showed a survival benefit in melanoma with adverse events (AEs) managed by protocol-
defined guidelines. A phase II study in lung cancer assessed the activity of ipilimumab plus
paclitaxel and carboplatin.
Purpose
Ipilimumab, which is an anti–cytotoxic T-cell lymphocyte-4 monoclonal antibody, showed a survival benefit in melanoma with adverse events (AEs) managed by protocol-defined guidelines. A phase II study in lung cancer assessed the activity of ipilimumab plus paclitaxel and carboplatin.
ose-immuno.com